eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

Early vs. standard zoledronic acid to prevent skeletal related events in prostate cancer

eagle-i ID


Resource Type

  1. Clinical trial


  1. Intervention
  2. Additional Topic(s)
    Bone fractures
  3. Additional Topic(s)
    Drug administration schedule
  4. Resource Description
    This randomized phase III trial is studying how well zoledronate works in preventing bone-related events in patients who are receiving androgen deprivation therapy for prostate cancer and bone metastases. Zoledronate may prevent or decrease skeletal (bone)-related events (such as pain or fractures) caused by bone metastases and androgen deprivation therapy.
  5. Contact
    Berenberg, Jeffrey
  6. PI
    Berenberg, Jeffrey
  7. Topic
    prostate cancer
  8. Study Population
    Men at least 18 years old, more than 1 year since hormone therapy that lasted no more than 6 months, and no more than 3 months since starting current androgen deprivation therapy. At least 4 weeks since radiation therapy. No previous bisphosphonates (such as zoledronate).
  9. Funded by
    Cancer Trials Support Unit
  10. Phase
    Phase 3 clinical trial
  11. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
  1. workflow state
  2. contributor
  3. created
  4. creator
    awendicke (Annemarie Wendicke)
  5. modified
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016